Impetigo: An Overview

Pediatric Dermatology

Volumn 11, Issue 4, 1994, Pages 293-303

  Darmstadt, Gary L ^a   Lane, Alfred T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFACLOR; CEFALEXIN; CEFPROZIL; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; FIBRONECTIN; FIBRONECTIN RECEPTOR; PENICILLIN G; PSEUDOMONIC ACID;

BACTERIAL COLONIZATION; BACTERIAL SKIN DISEASE; CELLULITIS; FURUNCULOSIS; HOST RESISTANCE; HUMORAL IMMUNITY; IMPETIGO; IMPETIGO BULLOSA; PRIORITY JOURNAL; REVIEW; SKIN FLORA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS GROUP A;

ANTIBIOTICS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE; HUMAN; IMPETIGO;

EID: 0028580647     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.1994.tb00092.x     Document Type: Article

References (92)

1. A survey of skin disorders seen in pediatric general and dermatology clinics
2. Skin diseases encountered in a pediatric clinic
3. Microbiology of the skin: resident flora, ecology, infection
4. Skin carriage of micococcaceae
5. The epidemiology and prevention of staphylococcal infection
6. Nasal and vaginal Staphylococcus aureus in young women: quantitative studies
7. Nasal carriage of staphylococci and streptococci
8. Staphylococcus aureus in the lesions of atopic dermatitis
9. Microbial flora of atopic dermatitis
10. Body odor—the role of skin bacteria
11. Skin and skin infections in the patient at risk; carrier state of Staphylococcus aureus
12. Skin microbiology: coming of age
13. Effect of antibiotics on the nasal flora in acne patients
14. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis
15. Binding sites for streptococci and staphylococci in fibronectin
16. Adherence of pharyngeal and skin strains of group A streptococci to human skin and oral epithelial cells
17. The adherence of Staphylococcus aureus to human corneocytes
18. Staphylococcus aureus adherence to nasal epithelial cells: studies of some parameters
19. Bacterial adherence, colonization and pathogenicity
20. Bacterial interference: its effect on nursery acquired infection with Staphylococcus aureus I. Preliminary observations on artificial colonization of newborns
21. Recurrent staphylococcal infection in families
22. In vitro and in vivo antistaphylococcal activity of human stratum corneum lipids
23. Acetic, propionic, and oleic acid as the possible factors influencing the predominant residence of some species of Propionibacterium and coagulase negative Staphylococcus on normal human skin
24. Bacteriocins and antagonism: the killing fields
25. Natural antibiosis among skin bacteria as a primary defense against infection
26. Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies
27. A therapeutic update of superficial skin infections
28. Cost effectiveness of erythromycin versus mupirocin for the treatment of impetigo in children
29. Impetigo contagiosa: suppurative and non‐suppurative complications
30. Impetigo contagiosa III. Comparative efficacy of oral erythromycin, and topical mupirocin
31. Double‐blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin‐resistant Staphylococcus aureus strains
32. Experimental infections with group A streptococci in humans
33. Streptococcal immune responses in nephritis after skin infection
34. Management of pyogenic cutaneous infections
35. Natural history of impetigo. II. Etiologic agents and bacterial in teractions
36. Impetigo in childhood: changing epidemiology and new treatments
37. Experimental infection of the skin in the hamster simulating human impetigo. II. Assessment of various therapeutic regimens
38. The treatment of streptococcal skin infections
39. Demonstration of a bactericidal substance against beta‐hemolytic streptococci in supernatant fluids of streptococcal cultures
40. Natural history of impetigo. I. Site sequence of acquisition and familial patterns of spread of cutaneous streptococci
41. Streptococcal infections of the skin and its complications: Impetigo and nephritis
42. Impetigo: a reassessment of etiology and therapy
43. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo
44. Comparison of mupirocin and erythromycin in the treatment of impetigo
45. Observations on acute glomerulonephritis associated with impetigo
46. Differences between streptococcal infections of the throat and of the skin
47. Staphylococcal scalded skin syndrome: the expanded clinical syndrome
48. Bacterial disease
49. Poststreptococcal acute glomerulonephritis: fact and controversy
50. Clinico‐pathologic correlations in acute poststreptococcal glomerulonephritis
51. Acute glomerulonephritis in children. A review of the natural history with emphasis on prognosis
52. Acute glomerulonephritis in children: a review of 153 cases
53. Poststreptococcal glomerulonephritis. Current clinical and pathologic concepts
54. Occurrence and nature of glomerular lesions after group A streptococci infections in children
55. Attack rates of acute nephritis after type 49 streptococcal infection of the skin and of the respiratory tract
56. Topical mupirocin versus systemic erythromycin treatment for pybderma
57. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy
58. Suppression of the antistreptolysin O response by cholesterol and by lipid extracts of rabbit skin
59. Endemic nephritis and streptococcal infections in South Trinidad. Surveillance studies during the first year following a major epidemic
60. Specificity and sensitivity of the streptozyme test for the detection of streptococcal antibodies
61. Comparison of the streptozyme test with the antistreptolysin O, antideoxyribonuclease B, and antihyaluronidase tests
62. Studies in children with impetigo: bacteriology, serology, and incidence of glomerulonephritis
63. The influence of hexachlorophene scrubs on the response to placebo or penicillin therapy in impetigo
64. Further studies on the treatment of streptococcal skin infection
65. Practical aspects of bacterial skin infectious in children
66. Review of mupirocin ointment in the treatment of impetigo
67. Mupirocin: a review of its antibacterial activity, pharmacokinetic properties, and therapeutic use
68. Mupirocin resistance in staphylococci
69. Topical antibiotic therapy: current status and future prospects
70. Role of teichoic acid in the binding of Staphylococcus aureus to nasal epithelial cells
71. Vaginal colonization with Staphylococcus aureus in healthy women: a review of four studies
72. Nasal, axillary, and perineal carriage of Staphylococcus aureus among women: identification of strains producing epidermolytic toxin
73. Elimination of nasal carriage of Staphylococcus aureus with mupirocin (‘pseudomonic acid’)a controlled trial
74. The reaquisition of staphylococci by treated carriers: a demonstration of bacterial interference
75. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment
76. Attempts to erradicate methicillin‐resistant Staphylococcus aureus from a long‐term‐care facility with the use of mupirocin ointment
77. Nasal carriage of gentamycin and methicillin‐resistant Staphylococcus aureus treated with topical pseudomonicacid
78. Role of bacterial flora in the pathogenesis and management of atopic dermatitis
79. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients
80. Methicillin‐resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management
81. Bacterial infections of Hie skin
82. Comparison of amoxicillin and augmentin for the treatment of non‐bullous impetigo
83. Randomized comparative evaluation of augmentin and cefaclor in pediatric skin and soft‐tissue infections
84. Amoxicillin combined with clavulanic acid for the treatment of soft tissue infections in children
85. A therapeutic update of superficial skin infections
86. the Collaborative Antimicrobial Testing Group. BMY‐28100, a new oral cephalo‐sporin: antimicrobial activity against nearly 7000 recent clinical isolates, comparative potency with other oral agents, and activity against beta‐lactamase producing isolates
87. Cefprozil versus cefaclor in the treatment of mild to moderate skin and skin‐structure infections
88. Clinical trials of cefprozil for treatment of skin and skin‐structure infections: review
89. Clinical trials of cefpodoxime proxetil suspension in pediatrics
90. Comparative safety and efficacy of clarithromycin and cefadroxil suspensions in the treatment of mild to moderate skin and skin structure infections in children
91. Clinical experience with clindamycin hydrochloride: I. Treatment of streptococcal and mixed streptococcal‐staphylococcal skin infections
92. Erythromycin in the treatment of streptococcal infections